Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $65.45

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned a consensus rating of “Moderate Buy” from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $65.45.

A number of equities analysts recently issued reports on the company. Morgan Stanley assumed coverage on Kymera Therapeutics in a report on Thursday, July 3rd. They issued an “overweight” rating and a $70.00 price objective for the company. B. Riley upped their target price on Kymera Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank Of Canada initiated coverage on Kymera Therapeutics in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 target price for the company. Truist Financial upped their target price on Kymera Therapeutics from $53.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. Finally, Citigroup upped their target price on Kymera Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, October 17th.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $59.19, for a total value of $295,950.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 176,910 shares of company stock valued at $9,572,948. 16.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV increased its stake in Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after purchasing an additional 328 shares in the last quarter. Neo Ivy Capital Management purchased a new position in shares of Kymera Therapeutics in the first quarter worth approximately $395,000. GSA Capital Partners LLP increased its position in shares of Kymera Therapeutics by 6.8% in the first quarter. GSA Capital Partners LLP now owns 31,537 shares of the company’s stock worth $863,000 after acquiring an additional 1,997 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock valued at $143,183,000 after acquiring an additional 344,080 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Kymera Therapeutics by 36.9% in the 1st quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock valued at $1,152,000 after acquiring an additional 11,343 shares in the last quarter.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $60.85 on Friday. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $63.96. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of -17.54 and a beta of 2.26. The business has a 50 day simple moving average of $50.95 and a 200 day simple moving average of $43.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period last year, the company earned ($0.58) earnings per share. The business’s quarterly revenue was down 55.1% compared to the same quarter last year. On average, equities analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.